Search research articles
Contact Us
Filters
Showing results (91-100 of 96) with videos related to
Page
of 10
Sort By:
You have reached the last page of results.
This site can display upto 96 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 13, 2007
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers
C Mazouni, S-W Kau, D Frye, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract
|
September 11, 1999
Prognostic factors in resectable pancreatic cancer: p53 and bcl-2
R J Bold, K R Hess, A S Pearson, et al.
Annals of Surgical Oncology
|
March 22, 2001
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration
T M Breslin, K R Hess, D B Harbison, et al.
Endocrine-Related Cancer
|
December 3, 2005
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding
W F Symmans, D J Fiterman, S K Anderson, et al.
NPJ Breast Cancer
|
December 15, 2017
A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline <i>BRCA</i> mutation demonstrates marked activity
J K Litton, M Scoggins, D L Ramirez, et al.
ESMO Open
|
March 15, 2021
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study
T Cascone, R L Sacks, I M Subbiah, et al.
Page
of 10
Search research articles
Search
Showing results (91-100 of 96) with videos related to
Sort By:
Page
of 10
You have reached the last page of results.
This site can display upto 96 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 13, 2007
Inclusion of taxanes, particularly weekly paclitaxel, in preoperative chemotherapy improves pathologic complete response rate in estrogen receptor-positive breast cancers
C Mazouni, S-W Kau, D Frye, et al.
Journal of Gastrointestinal Surgery : Official Journal of the Society for Surgery of the Alimentary Tract
|
September 11, 1999
Prognostic factors in resectable pancreatic cancer: p53 and bcl-2
R J Bold, K R Hess, A S Pearson, et al.
Annals of Surgical Oncology
|
March 22, 2001
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration
T M Breslin, K R Hess, D B Harbison, et al.
Endocrine-Related Cancer
|
December 3, 2005
A single-gene biomarker identifies breast cancers associated with immature cell type and short duration of prior breastfeeding
W F Symmans, D J Fiterman, S K Anderson, et al.
NPJ Breast Cancer
|
December 15, 2017
A feasibility study of neoadjuvant talazoparib for operable breast cancer patients with a germline <i>BRCA</i> mutation demonstrates marked activity
J K Litton, M Scoggins, D L Ramirez, et al.
ESMO Open
|
March 15, 2021
Safety and activity of vandetanib in combination with everolimus in patients with advanced solid tumors: a phase I study
T Cascone, R L Sacks, I M Subbiah, et al.
Page
of 10